

# A Patient perspective of Complementary and Integrative Medicine (CIM) for Migraine Treatment: A social media survey

Deena E Kuruvilla (✉ [deena.kuruvilla@yale.edu](mailto:deena.kuruvilla@yale.edu))

Amit Mehta

Yale University School of Medicine

Nidhi Ravishankar

Yale University School of Medicine

Robert Cowan

Stanford University School of Medicine

---

## Research article

**Keywords:** Integrative medicine, alternative medicine, headache, migraine, social media survey

**Posted Date:** May 4th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-25263/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

**OBJECTIVE:** To survey persons with migraine who use social media about Complementary and Integrative Medicine (CIM) for the treatment of migraine.

**BACKGROUND:** CIM encompasses medical treatments that are not part of ,but are used in concert with, mainstream medicine. Between 28–82% of people with migraine use non-drug approaches, and approximately 50% of people with migraine do not discuss non-drug treatments with their healthcare providers (HCPs) <sup>9</sup>. it is important for providers to be conversant with CIM treatments and the available evidence-based data. To further this effort, the Complementary and Integrative Medicine Special Interest Section (CIMSIS) of the American Headache Society surveyed migraine patients directly through social media to identify CIM practices in which they engage.

**METHODS:** In collaboration with the American Migraine foundation (AMF) and Yakkety Yak, a digital marketing agency, we posted a 17-question survey on the Move Against Migraine (MAM) Facebook group, which has 20,000 + members. The goals of the survey were to assess the attitudes toward CIM among this group, to identify which CIM modalities are being used and to determine what patients considered to be the most effective CIM modalities. While Yakkety Yak posted the survey link on the group page, the survey itself was hosted on Qualtrics, a confidential survey service. Qualtrics provides tools to configure survey properties and to customize privacy settings, so respondents cannot be tracked to an IP or email address, name or ticket number, which allows for anonymous responses. Our study was submitted for review to the IRB (institutional review board) and was exempted.

**RESULTS:** 372 MAM members (approximately 2%) responded to the questionnaire, of which 335 reported using CIM; between 114–139 (34–42%) found CIM modalities to be at least mildly effective. Of note, 164 (49%) reported using cannabis derivatives or cannabinoids, specifically with, 64/164 (39%) reporting that cannabis was not effective for them.

**CONCLUSIONS:** This study provides an initial investigation into the demographic and practice patterns of patients who use CIM. While it must this sampling may not reflect CIM use across all individuals with migraine, it does strongly suggest the need for better education on the role of, and evidence for, CIM among headache care providers, and the need to ask patients specifically about their use of and interest in CIM.

## Introduction:

Migraine affects 1 out of every 7 Americans annually and is 2 to 3 times more common in females than males <sup>1</sup>. The financial burden of migraine in the United States is estimated to be \$1,533 per patient annually for episodic migraine and \$4,144 for those with chronic migraine. Costs are higher in vulnerable or underserved populations, such as those who have low socioeconomic status, the uninsured, and the unemployed <sup>1</sup>.

While new migraine preventive and abortive treatments are emerging, research shows that a significant percentage of our patients are looking beyond standard medical treatments and incorporating complementary and integrative medicine (CIM). According to epidemiological studies, 28–82% of people with headache use CIM approaches<sup>6,7,8</sup>, while 50% of people with headache do not discuss their CIM treatments with their healthcare provider<sup>6</sup>.

CIM is defined by the National Center for Complementary and Integrative Health (NCCIH) as treatments that are separate from mainstream medicine but may be integrated with it<sup>6</sup>. NCCIH was previously called the National Center for Complementary and Alternative medicine (NCCAM) but was changed to NCCIH based on the escalation in use of complementary approaches by Americans. NCCIH more accurately reflects that Americans are no longer using these approaches “alternatively” but rather in conjunction with mainstream medicine. <sup>6</sup>Examples of CIM are commonly divided into two main categories: Natural products (herbs, vitamins, minerals and probiotics) and mind-body practices (yoga, chiropractic, meditation and massage therapy)<sup>6,9,10</sup>. Each category is further divided into a subcategory of CIM with meditation/yoga, herbal therapies, massage/chiropractic, and acupuncture being the top CIM in each category, respectively.

In 2012, the National Health Interview Survey reported on 88,962 American adults and 17,321 children and found 33.2% of adults and 11.6% of children used CIM in the previous 12 months<sup>7</sup>. Additionally, Americans spent \$30.2 billion on complementary health approaches during the same period<sup>7</sup>.

Educated women with migraine are more likely to use CIM<sup>8</sup>. Wells et al., using the 2007 National Health Interview Survey (n = 23,393) compared CIM use between adults with and without migraine/severe headache<sup>9</sup>. 49.5% of patients with migraine/severe headache used at least 1 Integrative treatment in the previous 12 months compared to 33.9% of patients without migraine/severe headache. Researchers noted that adults with migraine/severe headache used CIM more often for treatment because: their provider recommended it, mainstream treatment was ineffective, or mainstream and/or mainstream treatment was too expensive<sup>9</sup>.

Similarly, Rhee et al. used the 2012 National Health Interview Survey to estimate the prevalence rates of CIM use in adults with migraine/severe headache (n = 4447) and the reason behind their use (wellness, treatment or both)<sup>10</sup>. 41.3% of patients with migraine/severe headache stated they used CIM in the previous 12 months<sup>10</sup>. 29.6% used CIM for wellness only, 11.4% for treatment of migraine/severe headache and 59% for both wellness and treatment<sup>10</sup>. These data also show that only 31.3% of patients reported that a provider recommended CIM<sup>9</sup> and that fewer than 50% of adults with migraine/severe headaches discuss CIM use with their healthcare provider<sup>9</sup>.

To our knowledge, there are no publications using social media to investigate integrative methods used by migraine patients for treatment.

## Methods:

Permission was obtained from The American Migraine Foundation (AMF), Yakkety Yak and the Yale University institutional review board to post our survey on social media. The AMF and Yakkety Yak, a digital marketing agency, launched the nationwide #MoveAgainstMigraine campaign in 2017 to mobilize and empower people living with migraine. This initiative led to the creation of the Move Against Migraine (MAM) Facebook group for migraine patients to advocate on behalf of themselves, to understand treatment options, to access resources to manage migraine symptoms, and to connect with leading doctors and researchers. At the time of this study, the group had approximately 18,000 members.

Yakkety Yak posted our 17-question survey, created by the investigators, to the MAM Facebook community, for two months with reposting of the survey every 2 weeks between January 14,2019 – March 29,2019. The survey was voluntary, and no incentive was offered for completing it. The survey had not been used in previous studies and the questions were developed based on expert consensus from two University Headache centers. The target audience included patients who have used complementary and integrative medicine to treat and manage migraine. Consent was obtained from patients in order to participate in the survey. Anyone part of the (MAM) group was able to see the following post, and click on it if they wanted to participate:

Are you a migraine patient over the age of 18 who is living with migraine and using integrative remedies not prescribed by your physician (acupuncture, Coenzyme Q, cannabinoids, massage therapy, etc.)? Dr. Deena Kuruvilla, a headache specialist from Yale School of Medicine, is conducting a survey on the use of integrative medicines/therapies for migraines, and we need your help. Please click here to participate.

This study was submitted for review to the IRB and was granted an exemption. Consent was obtained from each member participating in the survey. When the participant clicked to participate in the survey, the first screen was a consent. They clicked a box in order to obtain their permission to complete the survey. While we specifically introduced our survey with migraine and integrative medicine in our social media link, we did have participants click on the link to confirm that they have not used integrative medicine. While Yakkety Yak posted the survey link on the group page, the survey itself was hosted on Qualtrics. Yakkety Yak did not have access to the collected data. Qualtrics provides tools that can be used to configure survey properties and to customize privacy settings, so respondents cannot be tracked to an IP or email address, name, ticket number, etc., which allows for anonymous responses. With these mechanisms as well as University firewall protected equipment, patient information was protected from unauthorized access. The data collected were used to better understand the integrative treatment methods used by migraine patients and to identify which methods are felt to be the most helpful. If any data were missing from participants, the participant survey was excluded using Qualtrics.

## Statistical Analysis

For a 95% confidence level, we estimated a margin of error using  $1/\sqrt{N}$ , where  $N$  is the sample size. With our sample size of 335, we estimated a 5% margin of error. Based on this calculation, we believe our

results are representative of a true population average. This analysis was descriptive in nature and therefore no formal hypothesis testing was conducted.

## Results:

A total of 412 patients responded to the survey. Of the 412 patients, only 377 (91.5%) completed the survey in its entirety. 5 (.013%) patients were never diagnosed with migraine by a medical professional, leaving 372 (99%) clinically diagnosed with migraine. 335 out of the 372 (90%) answered yes to “Do you use Complementary and Integrative Medicine (CIM) approaches to treat migraine.” 37 (9.9%) responded no to the above question. Of the patients who use CIM, 316 (94.3%) were female and 17 (5%) were male. Further demographics can be reviewed in **Table 2**. 247 users (73.7%) met the International Classification of headache disorders, 3rd edition (ICHD-3) diagnosis of chronic migraine while 87 users (25.9%) met criteria for episodic migraine. Specific questions were asked in the survey to differentiate episodic migraine and chronic migraine. 291 (86.6%) patients used CIM in combination with mainstream migraine treatments. Regarding how patients are seeking guidance for their CIM treatments, 68 (20.2%) are being managed by a healthcare provider, 24 (7.1%) patients utilize the internet, 12 (3.5%) seek help from a fellow person with migraine, 4 (1.1%) from a Naturopathic provider, and 193 (57.6%) from 2 or more of the above.

Patients were asked which category of CIM (Meditation, relaxation, deep breathing exercises, guided imagery, yoga, cognitive behavioral therapy, biofeedback, mindfulness training, craniosacral therapy, or migraine specific supplements/vitamins) they use. 19 (5.6%) patients use meditation, relaxation, breathing exercises, and/or guided imagery. 9 (2.6%) selected cognitive behavioral therapy, 2 (.59%) patients use craniosacral therapy, 4 (1.19%) use mindfulness training, 2 (.59%) selected biofeedback, 9 patients (2.6%) selected yoga, 63 (18.8%) selected vitamins, 189 (56.4%) patients answered that they use two or more of the above, and 45 (13.4%) selected other. **See Fig. 2**.

24 (5.9%) patients CIM treatments were very effective (50–100% reduction in headache days), 92 (22.6%) selected moderately effective (10–50% reduction), 139 (34.1%) slightly effective (1–10% reduction in headache days), 76 (18.6%) selected not effective at all (no change in headache days) and 76 (18.6%) did not answer.

With respect to nutraceutical use, 4 patients (1.19%) used Riboflavin, 78 (23.2%) use Magnesium, 4 (1.19%) selected Coenzyme q10, 1 (.298%) selected Butterbur, 15 (4.47%) selected other, 209 (62%) used a combination of 2 or more. 22 patients (6.56%) did not use any vitamin. **See Fig. 1**. Of those who used vitamins, 12 (3.58%) patients felt the vitamins were very effective (50–100% reduction in headache days), 58 (17.3%) selected moderately effective (10–50% reduction), 132 (39.4%) slightly effective (1–10% reduction in headache days), 109 (32.5%) not effective at all (no change in headache days) and 24 (7.1%) did not answer.

Although 10.7% of patients do not use any manipulation or body-based practices for migraine prevention, most (55.5%) use two or more therapies in combination. Of the individual therapies, participants reported

using, massage therapy was most frequently used (12.5%), then chiropractic maneuvers (9.2%), next acupuncture (9.0%—note: round all numbers to the same decimal point). Craniosacral therapy was minimally used (1.2%) as well as “other” therapies (1.7%). **See Fig. 3.** 27 (8.0%) patients answered that manipulation and/or body-based practices were very effective (50–100% reduction in headache days), 75 (22.3%) selected moderately effective (10–50% reduction), 114 (34%) patients selected slightly effective (1–10% reduction in headache days), 81 (24.1%) patients selected this CIM was not effective at all (no change in headache days) and 38 (11.3%) did not answer.

Finally, the survey ended with two questions regarding cannabinoids and their perceived effectiveness in preventing migraine. 164 (48.9%) use cannabidiol oil (CBD) or other cannabis derivative to prevent migraine and 171 (51%) selected no to this question. 4 (2.4%) of the 164 patients found CBD or other cannabis derivatives extremely effective; 14 (8.5%) found these products very effective (50–100% reduction in headache days), 36 (21.9%) selected moderately effective (10–50% reduction); 43 (26.2%) found them slightly effective (1–10% reduction in headache days); 64 (39%) patients found CBD or other cannabis derivatives not effective at all (no change in headache days). **See Fig. 4.**

## Discussion:

Our study is the first of its kind to identify social media as a vehicle to investigate common CIM approaches used by migraine patients for headache relief. There have however been other online survey studies. Lee et al. administered a 30-minute self-report survey on an online migraine headache resource (Migraine in America, [www.migraine.com](http://www.migraine.com)) to investigate if CIM produced a negative life impact of headaches for chronic migraine patients<sup>11</sup>. They found that approximately half of the participants reported using three CIM treatments and yet, felt dissatisfied or indifferent to their treatment strategy. They also found that migraine patients who use CIM were more likely to have more frequent migraine headaches.

Only 20.2% of participants in our study seek guidance for their CIM strategies specifically by a healthcare provider (MD, DO, NP, PA), while over 50% of patients seek guidance using multiple other strategies such as research the internet, guidance from a fellow migraine sufferer, or guidance from a Naturopathic provider. It is crucial that physicians query patients about their use of herbs, supplements, and vitamins with their standard treatment, provide realistic expectations, and identify potential treatment adverse effects, drug-drug interactions and existing evidence base. Patients using butterbur for example, must be counseled to obtain pyrrolizidine-alkaloid-free formulations due to the potential for hepatotoxicity. Liver function must be closely monitored while using this supplement.

In combination with the migraine vitamins, many patients used meditation, relaxation, deep breathing exercises, guided imagery, yoga, cognitive behavioral therapy, biofeedback, mindfulness training, and craniosacral therapy concurrently with the majority (56.4%) using 2 or more of these treatments. Of those, 76.7% of respondent patients found the combination moderately to very effective, This finding supports

previous evidence that these strategies were being used in the general population<sup>19</sup> and in other select populations<sup>19-22</sup> due to and the combination of low-cost and ease of access.

The evidence for using mind-body relaxation techniques recommended by the US Headache Consortium Guidelines<sup>23</sup> is based on the Agency for Health Care Policy and Research Technical Review, which found relaxation training (progressive muscle relaxation, autogenic training, meditation or passive relaxation), electromyography (EMG) biofeedback, and thermal biofeedback combined with relaxation training to have high quality (Grade A) evidence from well-performed research studies for the prevention of migraine<sup>24</sup>.

From our study, 30.3% patients found patients perceived any manipulation or body-based practices such as acupuncture, chiropractic maneuvers, etc. alone provided moderately to very effective treatment.<sup>25</sup>

Finally, only 30.4% of respondent patients using cannabis as a treatment for moderate/severe migraine found it moderately to very effective. As early as third and fourth centuries BCE, Ayurvedic preparations used cannabis for “diseases of the head” like migraine<sup>26</sup>. It is postulated that cannabis shows potential to interrupt glutamate signaling leading to cortical spreading depression<sup>27</sup>, serotonin release from platelets<sup>28</sup>, cranial blood vessel dilation caused by NO and CGRP<sup>29</sup>. While some studies have shown a significant impact of cannabis treating migraine<sup>30</sup> and increased efficacy for medication overuse headache<sup>31</sup>, properly constructed placebo-controlled trials are required to determine efficacy and side effects.

If patients and providers can have shared goals about integrative medicine use in migraine, they can have an open, non-judgmental dialogue about the risks and benefits of various approaches. The C.A.R.E mnemonic can be used when discussing CIM approaches with patients. Patients may have a specific perspective regarding treatment options based on their previous treatment experiences. It can be helpful to ask about their history with conventional treatments while also avoiding judgement. When reviewing integrative treatment options, it is imperative to counsel patients on their limitations so that they have appropriate expectations. Finally, in order to adequately educate patients on CIM, it is helpful to explore where the patient’s interest in CIM stems from. See table 1.

Many patients use complementary integrative medicine because it fits in with their attitudes about health<sup>32</sup>; addressing these beliefs, as well as potential benefits and complications, will improve patient-provider communication and more patient-centered care.

## **Limitations:**

Selection bias is inherent in all social media – based studies. We were only able to capture data from those patients who are currently active in the Facebook group being polled. This limits the data applicability to the wider migraine audience, of which a small portion may be overrepresented in this group. Other biases may be introduced by unforeseen variables.

We cannot regulate which users take part in the survey. The survey has questions designed to obtain information from patients who have a history or diagnosis of migraine; however, this cannot be confirmed. This is an unavoidable side effect of anonymous polling and may impact the reliability of the data. Although participants were advised to complete the survey once, the number of times the survey could have been completed by an individual was not regulated since the survey was anonymous through Qualtrics. The data presented in the text as well as the tables indicate “two or more therapies in combination”. We did not investigate which therapies were used in combinations.

This survey had not been previously validated or applied previously in studies. The study is also limited by a small sample size, a disproportionately large percentage of Caucasian female participants, and a predominantly chronic migraine population which is not representative of the larger migraine population within the United States. Many chronic migraine patients turn to CIM because they have been refractory to mainstream treatments. For this reason, the data in this study regarding patient responsiveness to CIM treatments must be interpreted with caution as many of the survey respondents may have been refractory to mainstream treatments. The responses seen in this survey may not be generalizable to the average patient.

## Conclusions:

This study provides an initial investigation into the demographic and practice patterns of patients who use CIM. While this sampling may not reflect CIM use across all individuals with migraine, it does strongly suggest the need for better education on the role of, and evidence for, CIM among headache care providers, and the need to ask patients specifically about their use of and interest in CIM.

## Abbreviations

CIM = Complementary and Integrative Medicine

NCCIH - National Center for Complementary and Integrative Health

NCCAM = National Center for Complementary and Alternative medicine

AMF = American Migraine Foundation

MAM = “Move Against Migraine” campaign

ICHD-3 = International Classification for Headache Disorders

EMG = Electromyography

C.A.R.E = **C**onventional treatment experience, **A**void judgement, **R**eview Integrative medicine options, **E**xplore complementary and Integrative medicine interest

# Declarations

## *Ethical Approval and Consent to participate*

*Ethical Approval and Consent to Participate* was obtained from study participants and the study has been approved by relevant *ethical* committee and the whole research process complies with *ethical* guidelines

## *Consent for Publication*

I, Deena Kuruvilla, give my consent for information about myself to be published in The Journal of Headache and Pain. I understand that the text and any pictures or videos published in the article will be freely available on the internet and may be seen by the general public. The pictures, videos and text may also appear on other websites or in print, may be translated into other languages or used for commercial purposes. I have been offered the opportunity to read the manuscript.

## *Availability of supporting data*

The data that support the findings of this study are available from the corresponding author upon reasonable request.

## *Competing interests*

The authors of this study do not have any competing interest during the submission process.

## *Funding*

No funding was received throughout the duration of this study

## *Authors' contributions*

DK developed the theoretical formalism, and with the help of AM, performed the analytic calculations and performed the numerical simulations. Both AM and NR authors contributed to the final version of the manuscript. RC supervised the project.

## *Acknowledgements*

I thank my colleagues at Yale University School of Medicine for their expertise and assistance throughout all aspects of our study.

# References

1. Burch R, Loder S, Loder E, Smitherman T (2015) The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. *Headache* 55:21–34. doi:10.4322/acr.2017.018

2. Marmura MJ, Silberstein SD, Schwedt TJ (2015) The Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies. *Headache: The Journal of Head Face Pain* 55(1):3–20. doi:10.1111/head.12499
3. Gilmore B, Michael M (2011) Treatment of Acute Migraine Headache. *Am Fam Physician* 83(3):271–280
4. Weatherall MW (2015) The diagnosis and treatment of chronic migraine. *Therapeutic Advances in Chronic Disease* 6(3):115–123. doi:10.1177/2040622315579627
5. Loder E, Rizzoli P (2018) Pharmacologic Prevention of Migraine: A Narrative Review of the State of the Art in 2018. *Headache: The Journal of Head Face Pain*. doi:10.1111/head.13375
6. Complementary, Alternative, or Integrative Health: What's In a Name? (2018, October 04) Retrieved from <https://nccih.nih.gov/health/integrative-health>
7. The Use and Cost of Complementary Health Approaches in the United States (2017, September 24) Retrieved from <https://nccih.nih.gov/about/strategic-plans/2016/use-cost-complementary-health-approaches>
8. Rhee TG, Harris IM (2016) Gender Differences in the Use of Complementary and Alternative Medicine and Their Association With Moderate Mental Distress in U.S. Adults With Migraines/Severe Headaches. *Headache: The Journal of Head Face Pain* 57(1):97–108. doi:10.1111/head.12986
9. Wells RE, Bertisch SM, Buettner C, Phillips RS, McCarthy EP (2011) Complementary and Alternative Medicine Use Among Adults With Migraines/Severe Headaches. *Headache: The Journal of Head Face Pain* 51(7):1087–1097. doi:10.1111/j.1526-4610.2011.01917.x
10. Rhee TG, Harris IM (2018) Reasons for and perceived benefits of utilizing complementary and alternative medicine in U.S. adults with migraines/severe headaches. *Complementary Therapies in Clinical Practice* 30:44–49. doi:10.1016/j.ctcp.2017.12.003
11. Lee J, Bhowmick A, Wachholtz A (2016) Does complementary and alternative medicine (CAM) use reduce negative life impact of headaches for chronic migraineurs? A national survey. *SpringerPlus*, 5(1). doi:10.1186/s40064-016-2362-7
12. Linnman C, Maleki N, Becerra L, Borsook D (2012) Migraine Tweets – What can online behavior tell us about disease? *Cephalalgia* 33(1):68–69. doi:10.1177/0333102412465207
13. Kristoffersen AE, Stub T, Salamonsen A, Musial F, Hamberg K (2014) Gender differences in prevalence and associations for use of CAM in a large population study. *BMC Complement Alternat Med* 14:463
14. Vaidya V, Partha G, Karmakar M (2012) Gender differences in utilization of preventive care services in the United States. *J Womens Health (Larchmt)* 21:140–145
15. Bertakis KD, Azari R, Helms LJ, Callahan EJ, Robbins JA (2000) Gender differences in the utilization of health care services. *J Fam Pract* 49:147–152
16. Manteuffel M, Williams S, Chen W, Verbrugge RR, Pittman DG, Steinkellner A (2014) Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. *J Womens Health (Larchmt)* 23:112–119

17. Bonetto N, Santelli L, Battistin L, Cagnin A (2007) Serotonin syndrome and rhabdomyolysis induced by concomitant use of triptans, fluoxetine and hypericum. *Cephalalgia* 27:1421–1423
18. Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin norepinephrine reuptake inhibitors: American Headache Society position paper. *Headache*. 2010; 50:1089–1099
19. Barnes PM, Bloom B, Nahin RL (2008) Complementary and alternative medicine use among adults and children: United States, 2007. *Natl Health Stat Rep* 12:1–23
20. Wells RE (2010) Phillips RS, Schachter SC, McCarthy EP. Complementary and alternative medicine use among US adults with common neurological conditions. *J Neurol* 257:1822–1831
21. Yeh GY (2006) Davis RB, Phillips RS. Use of complementary therapies in patients with cardiovascular disease. *Am J Cardiol* 98:673–680
22. Bertisch SM, Wee CC, McCarthy EP (2008) Use of complementary and alternative therapies by overweight and obese adults. *Obesity (Silver Spring)* 16:1610–1615
23. Campbell JK, Penzien DB, Wall EM. Evidencebased guidelines for migraine headache: behavioral and physical treatments. *US Headache Consortium 2000*. 2000. [Accessed July 14, 2009]. Available from <http://www.aan.com>
24. Goslin RE, Gray RN, McCrory DC, Penzien D, Rains J, Hasselblad V (1999) Behavioral and Physical Treatments for Migraine Headache. Research AfHCPa, Rockville
25. Rhee TG, Harris IM (2017) Gender Differences in the Use of Complementary and Alternative Medicine and Their Association With Moderate Mental Distress in U.S. Adults With Migraines/Severe Headaches. *Headache: The Journal of Head Face Pain* 57:97–108. doi:10.1111/head.12986
26. Gunther R, Goodyer J (1968) *The Greek herbal of Dioscorides: illustrated by a Byzantine, AD 512*. Hafner Publishing Company, New York
27. Juhasz G, Lazary J, Chase D et al (2009) Variations in the cannabinoid receptor 1 gene predispose to migraine. *Neurosci Lett* 461:116–120
28. Cupini LM, Costa C, Sarchielli P et al (2008) Degradation of endocannabinoids in chronic migraine and medication overuse headache. *Neurobiol Dis* 30:186–189
29. Osborn LA, Lauritsen KJ, Cross N et al (2015) Self-Medication of Somatic and Psychiatric Conditions Using Botanical Marijuana. *J Psychoactive Drugs* 47:345–335
30. Robbins MS, Tarshish S, Solomon S et al (2009) Cluster attacks responsive to recreational cannabis and dronabinol. *Headache* 49:914–916
31. Astin JA (1998) Why patients use alternative medicine: Results of a national study. *JAMA* 279:1548-1553

## Table

Table 1

Demographics for CIM users (N = 335)					
Male	17	18–24 years old	20	White	296
Female	316	25–34 years old	46	Hispanic or Latino	12
Prefer not to answer	1	35–44 years old	80	American Indian or Alaska Native	4
No Answer	1	45–54 years old	78	Asian	8
		55–64 years old	82	Native Hawaiian or Pacific Islander	0
		65 years old or over	29	Other	10
				Prefer not to answer	5

## Figures






Figure 1

Percent of Participants Using Natural Products




**Figure 2**

Percent of Participants Using Mind-Body Medicine



**Figure 3**

Percent of Patients Using Manipulative and Body-Based Practices



**Figure 4**

Percent of Patients with Degree of Effectiveness of Cannabinoid or Cannabis Derivatives Use